Mineralys Therapeutics Shares Financial Results and Corporate Developments for Q3 2025
November 11, 2025 - 02:53
Mineralys Therapeutics has announced its financial results for the third quarter of 2025, alongside significant updates regarding its corporate activities. The company is on track to submit a New Drug Application (NDA) for its promising medication, lorundrostat, anticipated for late 2025 or early 2026. This drug aims to address hypertension and related conditions, marking a pivotal moment in the company’s development pipeline.
In addition to the NDA plans, Mineralys has successfully completed enrollment in its Explore-OSA trial, a study focused on obstructive sleep apnea. Topline results from this trial are expected to be released in the first quarter of 2026, which could provide valuable insights into the efficacy of their treatment options.
The company will host a conference call today at 4:30 p.m. ET to discuss these developments in detail and provide further insights into their ongoing projects and future directions. Investors and stakeholders are keenly awaiting updates as Mineralys continues to progress in the biopharmaceutical landscape.
MORE NEWS
April 8, 2026 - 02:13
Hanmi Financial Corporation Announces First Quarter 2026 Earnings and Conference Call DateLOS ANGELES, April 07, 2026 -- Hanmi Financial Corporation, the parent company of Hanmi Bank, has officially scheduled the release of its financial results for the first quarter of 2026. The...
April 7, 2026 - 12:46
Economic calendarStaying ahead in the financial markets requires more than just watching daily price movements. A crucial tool for any informed investor is a comprehensive economic calendar, which consolidates key...
April 6, 2026 - 23:08
The Financial Stock Built for Investors Who Want Income Without the VolatilityFor income-focused investors weary of market turbulence, a unique real estate investment trust offers a compelling harbor. Realty Income Corporation has carved out a niche by providing shareholders...
April 6, 2026 - 10:29
Jim Cramer on Dow Inc.: “I Think You Should Kaching Kaching”Market commentator Jim Cramer has highlighted Dow Inc. as a stock to watch, following his review of first-quarter market performance. While analyzing the S&P 500`s top performers and the Nasdaq 100...